Aditxt Reports Significant Revenue Decline and Increased Losses in Latest 10-Q Filing

Aditxt, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated revenue of $748, a stark decline from $6,854 in the same quarter of the previous year. For the nine months ending September 30, 2025, total revenue was $2,770, down from $130,810 in the prior year. The cost of goods sold also decreased, amounting to $732 for the quarter and $2,471 for the nine-month period, compared to $467,536 and $556,469, respectively, in the previous year. The company reported a net loss of $24,207,669 for the quarter and $37,555,792 for the nine months, reflecting a substantial increase in losses compared to $6,980,313 and $29,472,886 for the same periods in 2024.

The filing highlighted several operational and strategic developments. Aditxt's general and administrative expenses decreased to $2,462,561 for the quarter, down from $3,718,804 in the prior year, primarily due to reduced payroll and professional fees. Research and development expenses also saw a rise to $672,045 from $491,552, indicating ongoing investment in product development despite the financial losses. The company has been actively pursuing capital raising efforts, including a Common Stock Purchase Agreement allowing for the issuance of up to $150 million in common stock, which could lead to significant dilution for existing shareholders.

Aditxt's operational metrics indicate a challenging environment, with cash reserves dwindling to $163,041 as of September 30, 2025, down from $833,031 at the end of the previous fiscal year. The company reported a working capital deficit of $20,238,149, raising concerns about its ability to continue as a going concern. The filing noted that Aditxt is over 90 days past due on several vendor obligations and will require substantial additional capital to fund ongoing operations and clinical studies.

Looking ahead, Aditxt's management expressed uncertainty regarding future profitability, emphasizing the need for significant capital to sustain operations and fund clinical trials. The company is focused on raising funds through various means, including equity and debt financing, but acknowledges that market conditions and the progress of its clinical development programs will heavily influence its ability to secure necessary funding. The filing underscores the risks associated with the company's financial health and operational viability, particularly in light of its limited revenue generation and ongoing losses.